130 related articles for article (PubMed ID: 12513962)
1. Positron emission tomography affects surgical management in recurrent colorectal cancer patients.
Desai DC; Zervos EE; Arnold MW; Burak WE; Mantil J; Martin EW
Ann Surg Oncol; 2003; 10(1):59-64. PubMed ID: 12513962
[TBL] [Abstract][Full Text] [Related]
2. Does positron emission tomography/computed tomography change management in colorectal cancer?
Falconer R; Connor S; Balasingam A; Eglinton T
ANZ J Surg; 2018 Apr; 88(4):E248-E251. PubMed ID: 27788564
[TBL] [Abstract][Full Text] [Related]
3. Effect of PET-CT on disease recurrence and management in patients with potentially resectable colorectal cancer liver metastases. Long-term results of a randomized controlled trial.
Serrano PE; Gu CS; Moulton CA; Husien M; Jalink D; Martel G; Tsang ME; Hallet J; McAlister V; Gallinger S; Levine M
J Surg Oncol; 2020 May; 121(6):1001-1006. PubMed ID: 32034769
[TBL] [Abstract][Full Text] [Related]
4. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.
Lai DT; Fulham M; Stephen MS; Chu KM; Solomon M; Thompson JF; Sheldon DM; Storey DW
Arch Surg; 1996 Jul; 131(7):703-7. PubMed ID: 8678767
[TBL] [Abstract][Full Text] [Related]
5. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?
Staib L; Schirrmeister H; Reske SN; Beger HG
Am J Surg; 2000 Jul; 180(1):1-5. PubMed ID: 11036130
[TBL] [Abstract][Full Text] [Related]
6. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
Metser U; You J; McSweeney S; Freeman M; Hendler A
AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
[TBL] [Abstract][Full Text] [Related]
7. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
[TBL] [Abstract][Full Text] [Related]
8. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography.
Ogunbiyi OA; Flanagan FL; Dehdashti F; Siegel BA; Trask DD; Birnbaum EH; Fleshman JW; Read TE; Philpott GW; Kodner IJ
Ann Surg Oncol; 1997 Dec; 4(8):613-20. PubMed ID: 9416407
[TBL] [Abstract][Full Text] [Related]
9. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver.
Zhuang H; Sinha P; Pourdehnad M; Duarte PS; Yamamoto AJ; Alavi A
Nucl Med Commun; 2000 Sep; 21(9):793-8. PubMed ID: 11065150
[TBL] [Abstract][Full Text] [Related]
10. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases.
Wiering B; Ruers TJ; Oyen WJ
Expert Rev Anticancer Ther; 2004 Aug; 4(4):607-13. PubMed ID: 15270664
[TBL] [Abstract][Full Text] [Related]
11. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
[TBL] [Abstract][Full Text] [Related]
12. [The role of positron emission tomography (PET) in the detection of local recurrence and metastases of colorectal cancer].
Kanyári Z; Orosz L; Juhász B; Tanyi M; Németh E; Trón L; Damjanovich L; Lukács G; Kálvin B
Magy Seb; 2005 Jun; 58(3):179-83. PubMed ID: 16167472
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
[TBL] [Abstract][Full Text] [Related]
14. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?
Selzner M; Hany TF; Wildbrett P; McCormack L; Kadry Z; Clavien PA
Ann Surg; 2004 Dec; 240(6):1027-34; discussion 1035-6. PubMed ID: 15570208
[TBL] [Abstract][Full Text] [Related]
15. Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases.
Georgakopoulos A; Pianou N; Kelekis N; Chatziioannou S
Clin Imaging; 2013; 37(3):536-41. PubMed ID: 23116727
[TBL] [Abstract][Full Text] [Related]
16. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging.
Schiepers C; Penninckx F; De Vadder N; Merckx E; Mortelmans L; Bormans G; Marchal G; Filez L; Aerts R
Eur J Surg Oncol; 1995 Oct; 21(5):517-22. PubMed ID: 7589597
[TBL] [Abstract][Full Text] [Related]
17. Accuracy of computed tomography in determining resectability for locally advanced primary or recurrent colorectal cancers.
Farouk R; Nelson H; Radice E; Mercill S; Gunderson L
Am J Surg; 1998 Apr; 175(4):283-7. PubMed ID: 9568652
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
19. Colorectal cancer. Radiologic staging.
Thoeni RF
Radiol Clin North Am; 1997 Mar; 35(2):457-85. PubMed ID: 9087214
[TBL] [Abstract][Full Text] [Related]
20. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer.
Valk PE; Abella-Columna E; Haseman MK; Pounds TR; Tesar RD; Myers RW; Greiss HB; Hofer GA
Arch Surg; 1999 May; 134(5):503-11; discussion 511-3. PubMed ID: 10323422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
